Global nutrition company, Arla Foods Ingredients has been granted exclusive commercialisation rights for its milk fat globule membrane (MFGM) product, Lacprodan MFGM-10, to be used in infant formula products in Australia.
MFGM occurs naturally in human milk and contains phospholipids, sphingolipids and gangliosides.
Its use comes after Food Standards Australia New Zealand (FSANZ) approved MFGM as a nutritive substance in infant formula products and the formal sign-off from the Australia and New Zealand Food Ministers Meeting.
Arla Foods said Lacprodan MFGM-10 was the first bovine MFGM ingredient for the global formula market, and studies have shown it has “the most clinical documentation for infant nutrition and immune health”.
In Australia, Lacprodan MFGM-10 can be labelled as “milk fat globule membrane-enriched whey protein concentrate”. However, New Zealand has opted out of the Australia-New Zealand joint infant formula products standard.
Earlier this year, the EU confirmed the product was not a novel food.
The decision means that Lacprodan MFGM-10 will be Arla Foods Ingredients’ first early life nutrition product to be approved by Australian authorities. It will also be the only MFGM ingredient approved for use in products for infants in the country for at least 15 months.
